文献速递甲状腺疾病

游离甲状腺素与中高危分化型甲状腺癌无进展生存期的关联

Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项纵向队列研究纳入382例中高危分化型甲状腺癌患者,均接受全甲状腺切除、放射性碘及TSH抑制治疗。年龄、肿瘤大小及侧颈淋巴结、骨、脑转移与更短无进展生存期相关。

要点

  • 游离甲状腺素升高与中高危分化型甲状腺癌无进展生存期无显著关联(HR 0.9,P=0.69)。
  • 年龄、肿瘤大小及侧颈淋巴结、骨、脑转移与更短无进展生存期相关。
  • 中高危分化型甲状腺癌患者中29.3%出现游离甲状腺素升高。

核心结论

  • 与临床前证据相反,游离甲状腺素水平升高不影响中高危分化型甲状腺癌患者的无进展生存期。

研究设计与样本

  • 纵向队列研究,经多机构审查委员会批准,纳入382例中高危分化型甲状腺癌患者,均统一接受全甲状腺切除、放射性碘及TSH抑制治疗,且至少3次TSH和游离甲状腺素值可用。

主要发现

  • 从739例筛选患者中,382例符合纳入标准,中位年龄46(34-59)岁,女性占64.1%,中位放射性碘剂量159(110-410)mCi。
  • 随访7.1(3.4-12.7)年期间,34.6%患者出现疾病进展。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Supraphysiologic T4 doses are used in intermediate- and high-risk patients with differentiated thyroid cancer (IR/HR-DTC) to suppress tumor progression by TSH. However, preclinical data suggest that T4 can also act as a growth stimulus for cancer, but there is no clinical evidence supporting this claim. OBJECTIVE: We analyzed the association between free T4 (FT4) and progression-free survival (PFS) in patients with IR/HR-DTC. METHODS: This longitudinal cohort study, approved by multi-institutional review board, included patients with IR/HR-DTC treated uniformly with total thyroidectomy, radioiodine, and TSH suppression therapy, with at least 3 TSH and FT4 values available. Association between FT4 and PFS at landmarks 6, 12, and 18 months was assessed by Kaplan-Meier survival curves, whereas competing risks were assessed through Cox proportional hazards model. RESULTS: From 739 screened patients, 382 met the inclusion criteria and were characterized by a median age of 46 (34-59) years, 64.1% women, and treated with a median radioiodine dosage of 159 (110-410) mCi. During follow up of 7.1 (3.4-12.7) years, 34.6% experienced disease progression. Elevated FT4, observed in 29.3% of patients, was not associated with worse PFS (hazard ratio [HR], 0.9; CI, 0.54-1.5; P = .69), whereas age (HR, 1.02; CI, 1.004-1.04; P = .01), tumor size (HR, 1.15; CI, 1.04-1.28; P = .01) and metastases to the lateral neck lymph nodes (HR, 2.9; CI, 1.7-4.74; P < .001), bones (HR, 4.87; CI, 1.79-13.3; P = .002), and brain (HR, 5.56; CI; 2.54-12.2; P < .001) were associated with shorter PFS. CONCLUSION: Contrary to preclinical evidence, elevated FT4 levels do not affect PFS in patients with IR/HR-DTC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ghosh R, Auh S, Gubbi S, et al. Association of Free Thyroxine With Progression-Free Survival in Intermediate and High-Risk Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39115341. doi:10.1210/clinem/dgae537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。